Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Biomed

29 stories about Biomed

The biomedical industry steps into the era of personalized healthcare
13.01.25|Dr. Merav Mor"Beyond technology, personalized medicine represents a profound conceptual shift. It invites us to rethink health, transitioning from reactive or preventive care to active partnerships between patients and the healthcare system," writes Dr. Merav Mor, co-founder of Lumen.
Somite.ai takes pre-seed to $10M as it eyes to become ‘the OpenAI of stem cell biology’
03.09.24|James SpiroThe company has received an extension of $4.8 million just six months after its initial raise for its novel cell replacement therapies.
Biomed company CartiHeal acquired by Smith & Nephew for up to $330 million
22.11.23|Meir OrbachThe Israeli firm, which develops a biocompatible, coral-based, off-the-shelf implant for damaged joints, will initially receive $180 million in cash and up to a further $150 million contingent on financial performance
Billionaire Steve Cohen leads $27.5 million investment in MediWound
05.02.23|Golan HazaniCohen's Point72 hedge fund invested $15 million in the round in what is believed to be the billionaire’s first investment in an Israeli company
Betalin Therapeutics receives EU equity investment for its alternative insulin therapy
21.07.21|James SpiroThe Biomed startup seeks to eliminate the need for insulin injections and glucose testing
Shuki Gleitman's GIBF raising $300 million in China for second biotech fund
31.05.21|Golan HazaniThe Guangzhou Sino-Israel Biotech Investment Fund (GIBF) focuses on life science investments and cooperates with leading Guangzhou organizations to bring Israeli biotech firms to the massive Chinese metropolitan
Moderna’s resigning CMO says he achieved what he cared about
25.02.21|Sophie ShulmanTal Zaks: I never imagined that I’d develop a vaccine for the worst pandemic of our times
Covid-19 was one of the biomed industry’s finest hours, says Israeli Silicon Valley veteran
15.12.20|Ron FriedmanAya Jakobovits, a trailblazer in the biomed sector who is participating in J-Ventures’ annual investor’s conference, speaks of how the coronavirus vaccines showcased the depth of new technology
Israel’s aMoon fund saw a 15-fold return on its investment in Seer
09.12.20|Sophie ShulmanaMoon invested in the U.S. biomed company when it was valued at $228 million- after a Nasdaq IPO, its value ballooned to $3.5 billion
Biomed at the focus of new Israel-UAE business cooperation
25.10.20|CTechNew cross-business initiative is led by Tel-Aviv based consultancy firm Kamir Strategy and UAE-based PR firm Cosmopole
IATI asks government to designate tech and biomed companies as essential industries
24.09.20|Hagar RavetAhead of the second lockdown, tech umbrella group urges decision-makers to allow the industry to keep specialized facilities open
250 companies and $6.5 billion: An in-depth look at Israel’s healthtech industry
27.08.20|Maya Perl, Ittai Harel, Guy EzekielIsraeli healthcare startups are no longer relying solely on technology, clinical data, or IP to generate value. They are reinventing business models and elevating the industry.
Biomed Company CartiHeal Considers a Nasdaq IPO
26.02.20|Golan HazaniThe company is looking to raise between $60 million and $80 million according to a valuation of $300 million to $400 million and has already hired Credit Suisse and Jefferies for this purpose, according to two people familiar with the matter
Exalenz Bioscience Acquired for $49M
19.02.20|Golan HazaniIsraeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company
19.02.20|Golan HazaniTel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source
FIMI Makes $25 Million Private Placement in Biomed Company Kamada
22.01.20|Tzally GreenbergIsrael-based private equity fund FIMI became the largest shareholder in Nasdaq and Tel Aviv-listed Kamada in November
FIMI Becomes Biggest Shareholder in Biomed Company Kamada
24.11.19|Golan Hazani and Tzally GreenbergNasdaq and Tel Aviv-listed Kamada develops protein-based pharmaceuticals for genetic disorders, as well as rabies antibodies and a serum against snake bites
Biomed Company BiomX Merges With New York-Listed Chardan Healthcare
17.07.19|Meir OrbachBiomX develops customized therapies for conditions such as acne and inflammatory bowel disease
Pi Therapeutics Raises $19.7 Million
29.05.19|Hagar RavetPi Therapeutics develops novel modulators of protein degradation for the treatment of cancer
Three Portfolio Companies of Len Blavatnik's Clal Biotechnology Raise Cash in One Week
04.07.18|CTechClal Biotechnology Industries is an Israel-based life sciences investment company

About CTech Terms of Use Privacy Policy

Back to Top